In a nutshell This study evaluated the safety and effectiveness of BCD chemotherapy (bendamustine, carboplatin, and dexamethasone) for patients with peripheral T-cell lymphoma that has come back or stopped responding to treatment. This study concluded that this treatment was promising, with minimal side effects. Some background Peripheral T-cell...
Read More
In a nutshell This study compared RTXM83 to rituximab (Rituxan) to see if it is as effective and safe for patients with diffuse large B-cell lymphoma. This study concluded that RTXM83 is as effective and safe as rituximab. Some background Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of non-Hodgkin’s lymphoma. This type...
Read More
In a nutshell This study investigated female fertility preservation (FFP) in cancer patients. They found that FFP should be discussed with all women of reproductive age undergoing cancer treatment. Some background Cancer can have many negative effects on patient health. Infertility is a particular concern for younger female patients. Pregnancy...
Read More
In a nutshell This study investigated the risk of developing secondary cancer in patients with follicular lymphoma (FL). This study concluded that this risk was low after first-line treatment, but increased with multiple lines of treatment. Some background Chemoimmunotherapy regimens involving rituximab (Rituxan) remain the standard of care for...
Read More
In a nutshell This phase 3 study is evaluating the effectiveness and safety of two different chemotherapy regimens for patients with mantle cell lymphoma (MCL). The main outcome to be measured will be the number of patients who survive without tumor growth or spread. This study is recruiting in Las Vegas, Nevada in the U.S. The details MCL is an...
Read More
In a nutshell This article provided guidelines for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL). Some background DLBCL and FL are the most common types of non-Hodgkin’s lymphoma in adults. FL has the potential to transform into a more aggressive type of lymphoma. The most common transformation...
Read More
In a nutshell This article reviewed the current treatment options for patients with mantle cell lymphoma (MCL). Some background MCL is a rare but aggressive type of non-Hodgkin’s lymphoma. Chemoimmunotherapy is the typical first-line treatment for MCL. 80 – 90% of patients respond to this treatment. However, many patients eventually have...
Read More
In a nutshell This study evaluated the effectiveness and safety of a new chemotherapy regimen for patients with non-Hodgkin’s lymphoma (NHL). This study concluded that this regimen was highly effective for these patients, but was associated with some side effects. Some background For patients with NHL, age is one determining factor for treatment...
Read More
In a nutshell This study examined the impact of aspartic transaminase (AST) levels in the blood on survival outcomes for patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that high levels of AST in the blood were associated with poorer treatment outcomes for these patients. Some background DLBCL is one of the most common types...
Read More
Nanodrugs have been around for some time. In fact, over 250 drugs using nanotechnology that have been approved by the FDA and are in clinical use. The name nanodrug or nanopharmaceuticals refers to the size of the particle that is created to house the medication. A nano is very tiny: nanoparticles are between 1 and 100 nanometers in at least one of its...
Read MoreIn a nutshell This phase 1/2 trial will investigate the safety of 9-ING-41, for treatment-resistant cancers. The main outcome will be the number of treatment-related adverse events (TRAEs). This trial is recruiting in the United States. The details Some cancers may not respond to conventional treatment. Treatment-resistant cancers are called...
Read MoreIn a nutshell This phase 1 study is evaluating the safety and effectiveness of a new T-cell therapy combined with nivolumab (Opdivo) for patients with lymphoma that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have side effects. This study is recruiting in Washington, D.C. and Salt...
Read More
